Clinical trials
Multiple Sclerosis, Relapsing-Remitting clinical trials
Below are recruiting multiple sclerosis, relapsing-remitting clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT07753928Enrolling by invitation
MRI study of brain changes in multiple sclerosis
This study uses MRI scans to measure how the brain changes over time in people with multiple sclerosis (MS). It may help researchers understand why some people with MS experience more disability, which could lead to better treatments.
DresdenAges 18–55 - NCT05958381Recruiting
Brain stimulation for memory problems in relapsing MS
This trial studies a noninvasive brain stimulation treatment to improve memory (specifically memory recall) in people with relapsing-remitting multiple sclerosis (RRMS). It may help if your memory testing shows a “retrieval” problem, and if you’re able to follow the study treatment and safety requirements.
Richardson, TexasAges 18–65 - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT03600779Recruiting
Advanced MRI scan for multiple sclerosis
This study uses a special MRI scan to look at brain damage caused by multiple sclerosis (MS). It may help doctors better understand the disease and could lead to better treatments.
Marseille, PACAAges 18–45 - NCT06796504Recruiting
Nerve stimulation for relapsing-remitting multiple sclerosis
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
Irvine, CaliforniaAges 22–60 - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT07736482Recruiting
How fatigue and disability affect obstacle stepping in MS
This study looks at how fatigue and disability affect your ability to step over an obstacle while walking—whether you are doing just that task or also doing a second task (like talking). It may help understand how MS affects everyday movement.
Afyonkarahisar, MerkezAges 18–65 - NCT03401879Recruiting
Study eye blood-flow changes in multiple sclerosis
This study measures how blood flow in the eye changes in people with relapsing-remitting multiple sclerosis (RRMS) who previously had optic neuritis. The goal is to understand eye/brain blood-flow signals and how they may relate to MS.
Vienna, AustriaAges 18 years+ - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT03910738RecruitingPhase 2
Testosterone treatment for nerve protection and myelin repair in MS
This Phase 2 study tests whether taking testosterone (for low testosterone levels) can help protect nerves and repair myelin in people with relapsing-remitting multiple sclerosis (MS). It may be most relevant if your MS is stable and you have low blood testosterone without current androgen treatment.
BesançonAges 18–55 - NCT04458688Recruiting
Ocrelizumab study for relapsing MS in African Americans and Caucasians
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Detroit, MichiganAges 18–60 - NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT04604041Recruiting
Study early warning signs in relapsing-remitting multiple sclerosis
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
SplitAges 18–65 - NCT05177523Recruiting
MRI study of nerve damage and repair in multiple sclerosis
This trial uses MRI scans to better understand how nerve fibers are damaged and repaired in people with multiple sclerosis. It may help researchers connect scan findings to disease activity and progression.
BaselAges 18–80 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05532943RecruitingPhase 1/Phase 2
Cord stem cell treatment for people with multiple sclerosis
This Phase 1/2 trial studies whether donated umbilical cord stem cells are safe and can improve multiple sclerosis. It aims to see if the treatment is workable for people who still have active MS despite standard therapies.
Taichung, Non-USAges 20–65 - NCT05748015Recruiting
Checking how the nervous system is affected in multiple sclerosis
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
Telese Terme, BeneventoAges 18 years+ - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05834855RecruitingPhase 3
Rituximab versus ocrelizumab for relapsing multiple sclerosis
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
AmsterdamAges 18 years+ - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT05961644RecruitingPhase 2/Phase 3
Cladribine vs placebo for non-active progressive multiple sclerosis
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
Warsaw, Masovian VoivodeshipAges 30–65 - NCT05962177Recruiting
Study of blood tests and scans in relapsing-remitting MS
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
MontpellierAges 18–59
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Multiple Sclerosis, Relapsing-Remitting trials by city
Studies with a site in or near these metro areas.
Multiple Sclerosis, Relapsing-Remitting trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for multiple sclerosis, relapsing-remitting?
- Yes. Clin2 currently lists 79 recruiting multiple sclerosis, relapsing-remitting studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis, relapsing-remitting trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis, relapsing-remitting trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis (MS) - Relapsing-remitting
- Relapsing Multiple Sclerosis
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Fatigue in Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.